The negative trailing P/E and elevated trailing EV/EBITDA reflect depressed and volatile EBITDA rather than a valuation signal that can be read directly against peers. The forward EV/EBITDA of 11.71 sits below peers such as Medpace at 31.94 and IQVIA at 17.18, suggesting the market is capitalizing a normalized earnings base that the reported 2026Q3 operating margin of 2.2% has not yet demonstrated. Investors should monitor whether the forward estimates prove achievable before treating the discount to peers as value.

The gross margin of 20.2% in the latest quarter is recovering but leaves SG&A consuming most of gross profit, which suggests limited operating leverage at current revenue levels. Net margin of 0.1% is essentially break-even and offers no buffer against revenue softness, so earning power appears structurally constrained rather than cyclically depressed. Investors may want to assess whether cost discipline can be sustained as revenue continues to decline modestly year over year.

The improvement in ROIC appears driven by margin recovery and reduced impairment-related losses rather than any sustained efficiency gain, since asset turnover remains low at 0.25. With equity of $532.3M and a retained deficit near $1.4B, ROE figures are sensitive to a small equity base, which may overstate the apparent recovery. Whether returns can compound toward peer levels remains unproven given the thin margin structure.

Coverage below 1.0x in the latest quarter indicates that operating earnings are only marginally sufficient to meet interest obligations, which warrants close monitoring given total debt of roughly $1.1B. The D/E swings appear largely tied to debt classification timing and a shrinking equity base, so the reported ratio may not reflect the underlying leverage trend. Investors should focus on whether interest coverage stabilizes above 1.0x as the reported recovery continues.